In the US market, the most expensive priced ADC drug is Pfizer's Bebosan (ocetuzumab), with an annual treatment cost of $290,000 for a 60kg patient, equivalent to nearly 2 million Chinese yuan (CNY 1.95 million). The next highest priced ADC is GSK's Blenrep, priced at 1.36 million yuan. These two are the only ADC drugs priced over one million yuan.

There are two ADC drugs priced over 500,000 yuan, namely Daiichi Sankyo/AstraZeneca's Enhertu (trastuzumab deruxtecan, used for breast cancer) at 910,000 yuan, and Roche's Polivy (polatuzumab vedotin) at 790,000 yuan.

There are three ADC drugs priced over 400,000 yuan, including AstraZeneca's Lumoxiti at 480,000 yuan, Roche's Herceptin (trastuzumab emtansine) at 440,000 yuan, and Daiichi Sankyo/AstraZeneca's Enhertu (trastuzumab deruxtecan, used for gastric cancer) at 420,000 yuan.

The lowest priced ADC is Seagen/Astellas' Enfortumab vedotin, priced at 260,000 yuan.

In the Chinese market, Roche's Herceptin (trastuzumab emtansine) is priced at 330,000 yuan. The lowest priced domestic ADC drug in China is Rongchang Biotech's Aidixi (vedotin), priced at only 84,000 yuan.

Three ADC drugs have been included in the china national medical insurance after price negotiations. In addition to Rongchang Biotech's Aidixi, there are Roche's Polivy and Seagen/Takeda's Vicinium. (See Figure 1 for details.),

Enhertu (trastuzumab deruxtecan), domestically available, has a market price of only 8,860 Chinese yuan per vial, which is about 30% lower than purchasing it overseas. After receiving charitable drug donations, patients pay less than 20,000 yuan out of pocket for each treatment course, and less than 27,000 yuan per month on average. If combined with local healthcare subsidies, patients only need to pay around 18,000 yuan per month on average.

Regarding purchasing medication overseas, you can refer to the Hong Kong Cancer Drugs website at https://www.drugshk.com/.